AstraZeneca plc (LON:AZN)‘s stock had its “neutral” rating reissued by equities research analysts at JPMorgan Chase & Co. in a research note issued to investors on Tuesday. They presently have a GBX 4,200 ($51.87) price objective on the biopharmaceutical company’s stock. JPMorgan Chase & Co.’s price objective points to a potential downside of 14.29% from the stock’s current price.

Several other brokerages also recently weighed in on AZN. Bryan, Garnier & Co reaffirmed a “buy” rating and issued a GBX 5,100 ($62.99) target price on shares of AstraZeneca plc in a report on Tuesday, November 22nd. HSBC Holdings plc reaffirmed a “hold” rating and issued a GBX 4,700 ($58.05) target price on shares of AstraZeneca plc in a report on Wednesday, November 23rd. Deutsche Bank AG reaffirmed a “buy” rating and issued a GBX 6,000 ($74.10) target price on shares of AstraZeneca plc in a report on Wednesday, November 30th. Berenberg Bank reaffirmed a “buy” rating and issued a GBX 5,500 ($67.93) target price on shares of AstraZeneca plc in a report on Tuesday, December 6th. Finally, Liberum Capital reaffirmed a “hold” rating and issued a GBX 5,200 ($64.22) target price on shares of AstraZeneca plc in a report on Thursday, December 8th. Four research analysts have rated the stock with a sell rating, eight have given a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. AstraZeneca plc presently has an average rating of “Hold” and an average target price of GBX 5,018.36 ($61.98).

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Shares of AstraZeneca plc (LON:AZN) opened at 4900.00 on Tuesday. The firm’s market cap is GBX 62.00 billion. AstraZeneca plc has a 12-month low of GBX 3,680.00 and a 12-month high of GBX 5,505.00. The firm has a 50-day moving average of GBX 4,617.49 and a 200-day moving average of GBX 4,602.58.

The firm also recently announced a dividend, which was paid on Monday, March 20th. Shareholders of record on Thursday, February 16th were given a dividend of GBX 150.20 ($1.86) per share. The ex-dividend date was Thursday, February 16th. This represents a yield of 3.52%. This is a boost from AstraZeneca plc’s previous dividend of $68.70.

Your IP Address:

About AstraZeneca plc

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.

Receive News & Stock Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related stocks with our FREE daily email newsletter.